- Home
- PPBT vs PAVM Comparison
PPBT vs PAVM Comparison
Compare PPBT & PAVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- PAVM
- Stock Information
- Founded
- PPBT 2010
- PAVM 2014
- Country
- PPBT Israel
- PAVM United States
- Employees
- PPBT N/A
- PAVM N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- PAVM Medical/Dental Instruments
- Sector
- PPBT Health Care
- PAVM Health Care
- Exchange
- PPBT Nasdaq
- PAVM Nasdaq
- Market Cap
- PPBT 6.2M
- PAVM 12.0M
- IPO Year
- PPBT N/A
- PAVM 2016
- Fundamental
- Price
- PPBT $2.40
- PAVM $0.59
- Analyst Decision
- PPBT Strong Buy
- PAVM Strong Buy
- Analyst Count
- PPBT 1
- PAVM 1
- Target Price
- PPBT $33.00
- PAVM $19.00
- AVG Volume (30 Days)
- PPBT 20.0K
- PAVM 135.4K
- Earning Date
- PPBT 08-15-2025
- PAVM 08-11-2025
- Dividend Yield
- PPBT N/A
- PAVM N/A
- EPS Growth
- PPBT N/A
- PAVM N/A
- EPS
- PPBT N/A
- PAVM 0.96
- Revenue
- PPBT N/A
- PAVM $1,993,000.00
- Revenue This Year
- PPBT N/A
- PAVM N/A
- Revenue Next Year
- PPBT N/A
- PAVM $455.63
- P/E Ratio
- PPBT N/A
- PAVM $0.62
- Revenue Growth
- PPBT N/A
- PAVM N/A
- 52 Week Low
- PPBT $2.00
- PAVM $0.54
- 52 Week High
- PPBT $13.95
- PAVM $1.90
- Technical
- Relative Strength Index (RSI)
- PPBT 47.27
- PAVM 45.52
- Support Level
- PPBT $2.35
- PAVM $0.54
- Resistance Level
- PPBT $2.58
- PAVM $0.61
- Average True Range (ATR)
- PPBT 0.12
- PAVM 0.03
- MACD
- PPBT 0.01
- PAVM 0.00
- Stochastic Oscillator
- PPBT 43.75
- PAVM 54.54
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.